China’s NMPA to Expand Early Guidance for Novel-Drug Innovation

The shift here is regulatory, not promotional: China is moving earlier in the drug-development cycle, offering guidance before trials are designed rather than after filings arrive. Pairing that with data protection and exclusivity for pediatric and rare-disease drugs signals an attempt to make difficult, low-commercial-priority categories viable for developers. Extending the device program to brain-computer interfaces hints at where frontier approvals may cluster. Whether these incentives translate into actual pipelines, rather than earlier conversations alone, is the open question.